10x Genomics (NASDAQ: TXG) narrows 2025 losses and guides to modest 2026 growth
10x Genomics reported significantly narrowed losses in 2025, driven by improved profitability and reduced operating expenses, despite only modest revenue growth. The company also provided cautious revenue guidance for 2026, projecting 0% to 4% growth when excluding one-time patent litigation settlement revenue from 2025. This financial update highlights a strategic shift towards profitability amidst a challenging market, supported by strong cash reserves and strategic partnerships.
10x Genomics Earnings Preview: Revenue Forecast, Analyst Estimates & Stock Outlook - News and Statistics
10x Genomics is set to release its Q4 2025 earnings report this Thursday, with analysts forecasting a revenue of $159.2 million and an adjusted loss per share of $0.04. The company previously beat revenue and EPS estimates in the last quarter, though its stock has recently declined by 4.5%. The broader life sciences tools and services sector has also underperformed, while discussions about tariffs and corporate tax changes add to economic uncertainty.
UK project turns decades of NHS cancer samples into AI-ready data
10x Genomics has partnered with PharosAI, a UK consortium, in an £18.9 million initiative to convert thousands of archived NHS cancer samples into one of the world's largest multimodal datasets. This project aims to create AI-ready genomic, transcriptomic, imaging, and spatial biology data to accelerate cancer diagnosis, precision therapies, and drug discovery. The program, backed by the UK Research Ventures Catalyst and running through 2027, will democratize secure access to these datasets for researchers globally.
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
PharosAI, a research consortium backed by £18.9 million from the UK Government, is partnering with 10x Genomics to create one of the world's most comprehensive multimodal cancer datasets. They will use 10x Genomics' Xenium spatial platform to analyze archived NHS cancer samples and build advanced AI models for earlier diagnosis, precision therapies, and new treatment discovery, initially focusing on breast cancer. The initiative aims to democratize access to these AI-ready datasets for researchers and innovators globally.
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
PharosAI, a research consortium backed by £18.9 million from the UK Government and other partners, is partnering with 10x Genomics to create one of the world's most comprehensive multimodal cancer datasets using AI and spatial biology. The initiative will leverage 10x Genomics' Xenium spatial platform to transform archived NHS cancer samples into high-resolution datasets, which will be paired with advanced AI models to accelerate earlier diagnosis, enable precision therapies, and speed the discovery of new treatments, starting with breast cancer. This collaboration aims to democratize access to these datasets, positioning the UK at the forefront of AI-driven cancer research.
New study tracks blood signals to guide care for autoimmune disease patients
10x Genomics (NASDAQ: TXG) has announced a collaboration with Brigham & Women's Hospital to launch a blood-based, single-cell study on autoimmune diseases, enrolling 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. The study aims to identify immune signatures linked to disease activity, flare, remission, and treatment response to develop a framework for future clinical reports. This initiative is part of 10x Genomics' multi-year strategy to advance research in blood-based diagnostics and potentially establish a CLIA-certified laboratory for clinical applications.
Sumitomo Mitsui Trust Group Inc. Sells 636,744 Shares of 10x Genomics $TXG
Sumitomo Mitsui Trust Group Inc. reduced its stake in 10x Genomics (NASDAQ:TXG) by 10.6% in the third quarter, selling 636,744 shares and retaining ownership of 5,381,219 shares valued at approximately $62.9 million. The article also notes recent insider sales by Benjamin J. Hindson and CEO Serge Saxonov, and that the company reported Q3 revenue of $149 million with an EPS of -$0.22, beating estimates. Analyst consensus for 10x Genomics is currently "Hold" with an average target price of $16.30.
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease
10x Genomics has partnered with Brigham & Women's Hospital to conduct a study aimed at identifying single-cell immune signatures in patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. This collaboration seeks to develop blood-based diagnostic tools to better understand disease activity, flare, remission, and treatment response in autoimmune diseases. The ultimate goal is to enable personalized medicine in rheumatology by integrating single-cell genomics into clinical workflows and constructing a framework for future clinical reporting.
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease
10x Genomics (Nasdaq: TXG) has announced a collaboration with Brigham & Women's Hospital to conduct a study aimed at advancing blood-based diagnostics for autoimmune diseases. The research will analyze peripheral blood samples from 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis using single-cell profiling to identify immune signatures associated with disease activity and treatment response. This initiative seeks to provide clinicians with better tools for diagnosing and managing complex autoimmune conditions and support personalized medicine in rheumatology.
New research map aims to explain why some organ transplants fail
CareDx and 10x Genomics are collaborating on the ImmuneScape™ program, a multiomics research initiative to understand organ transplant rejection and drug response. This program will use advanced single cell and spatial biology technologies to create high-resolution maps of immune mechanisms involved in rejection. The goal is to generate insights that could lead to new clinical diagnostics and personalized transplant medicine, ultimately improving outcomes for transplant patients.
10x Genomics (TXG) Gains as Analysts Raise Price Targets in Early 2026 - News and Statistics
Shares of 10x Genomics (NASDAQ:TXG) rose by 2.5% on January 2, 2026, following several analyst price target increases, including Barclays, BofA, and Canaccord Genuity. Analysts cited factors like recovering end markets and fading headwinds for their increased optimism. Despite the initial gain, the shares settled to a 0.7% rise, indicating the market viewed the news as meaningful but not fundamentally transformative for the volatile stock.
10x Genomics (Nasdaq: TXG) Xenium Powers ASTRA Atlas of 2,000 Asia-Pacific Tumor Samples
10x Genomics, alongside the Garvan Institute and the University of Tokyo, launched the Asia-Pacific Spatial Translational Research Alliance (ASTRA) on November 18, 2025. This consortium aims to create a pan-cancer spatial atlas of 2,000 tumor samples using 10x Genomics' Xenium platform, focusing on ten major cancer types. ASTRA will establish regional hubs and a shared digital infrastructure to harmonize biospecimens and data, advancing precision oncology across the Asia-Pacific region.
10x Genomics Announces Chief Legal Officer Retirement
10x Genomics announced that its Chief Legal Officer, Eric S. Whitaker, will retire on January 1, 2026, after over eight years of service, transitioning to Strategic Counsel. Dr. Randy Wu will succeed him as General Counsel and Secretary. The company's stock (TXG) currently holds a "Hold" analyst rating with an $18 price target, and Spark’s AI Analyst describes TXG as Neutral, citing strong technical performance but weak financial results.
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium
The Asia-Pacific Spatial Translational Research Alliance (ASTRA) has been formed by researchers from the Garvan Institute of Medical Research in Australia and the University of Tokyo in Japan. This consortium, supported by 10x Genomics' Xenium platform, aims to create a comprehensive pan-cancer spatial atlas by mapping cancer and immune cell interactions across 2,000 tumor samples. The initiative seeks to advance precision oncology in the Asia-Pacific region by providing a shared foundation that integrates molecular and spatial data, addressing the current underrepresentation of these insights in global cancer data.
TXG announces CLO retirement; Randy Wu to serve as General Counsel
10x Genomics (TXG) announced a planned legal leadership transition with Eric S. Whitaker retiring as Chief Legal Officer on January 1, 2026, after over eight years of service. He will transition to Strategic Counsel. Dr. Randy Wu, currently VP of Intellectual Property and Litigation, will succeed Whitaker as General Counsel and Secretary, also effective January 1, 2026.
10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research
10x Genomics has launched the next generation of its Chromium Flex assay, featuring automation-compatible plate-based multiplexing that enables highly scalable and cost-effective single cell analysis. This new assay allows researchers to profile up to 384 samples and 100 million cells per week, expanding the scope of single cell studies to previously unachievable scales and applications. The technology aims to accelerate drug discovery and translational research by providing more data at a lower cost, addressing the growing need for high-quality biological data in AI-driven approaches.
10X Genomics (NASDAQ:TXG) Surges 13% on Q3 Revenue Beat and Strong Guidance
10X Genomics (NASDAQ:TXG) saw its shares surge over 13% after reporting a mixed third quarter for 2025. The company beat analyst expectations for revenue and non-GAAP EPS, reporting $149 million in revenue against an estimated $143.9 million, and a loss of $0.22 per share compared to an estimated loss of $0.29. The positive market reaction was also driven by strong forward guidance for Q4 2025, with a midpoint revenue forecast of $156 million, exceeding analyst expectations of $150.7 million.
CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics
CLISEQ, 10x Genomics, and the Weizmann Institute have announced a multi-year international clinical research study to evaluate single-cell RNA sequencing (scRNA-seq) from peripheral blood as a minimally invasive alternative to bone marrow aspiration for diagnosing hematologic disorders. The PERIBLOOD clinical trial aims to enroll over 1,500 participants globally. This collaboration seeks to improve diagnostics for blood malignancies by leveraging advancements in single-cell technology to enable non-invasive molecular diagnostics and monitoring.
Illumina Hit with 10X Genomics Patent Suits Over Sequencing Tech
10X Genomics Inc. has sued Illumina Inc., alleging infringement of nine patents related to single-cell genetic sequencing and spatial technology. Two lawsuits were filed in the US District Court for the District of Delaware, with Prognosys Biosciences Inc. and Roche Sequencing Solutions Inc. as co-plaintiffs in respective cases. Illumina denies the allegations and plans to vigorously defend itself.
Earnings call transcript: 10X Genomics Q2 2025 beats EPS expectations
10X Genomics (NASDAQ: TXG) reported strong Q2 2025 results, beating EPS expectations with $0.28 against a forecast of -$0.37, and revenue reaching $173 million, exceeding estimates by 24.03%. Despite positive financial performance and a turn to net income, the stock fell 2.92% in after-hours trading due to market caution and an uncertain funding environment. The company highlighted growth in consumables, particularly Xenium, and announced the strategic acquisition of Scale Biosciences to enhance its single-cell analysis platform.
10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025
10x Genomics (NASDAQ: TXG) will release its third-quarter 2025 financial results after the market closes on Wednesday, November 6, 2025. The company will also host a conference call and webcast to discuss these results at 2:00 PM Pacific Time / 5:00 PM Eastern Time on the same day. A replay of the webcast will be available on the 10x Genomics investor website for approximately three months.
10x Genomics, Inc. (TXG) Stock Analysis: Evaluating The 31.90% Potential Upside
This article analyzes 10x Genomics, Inc. (TXG) stock, highlighting its potential 31.90% upside based on analyst ratings within the challenging healthcare sector. It details the company's profile, market position with cutting-edge genomic analysis technologies, current stock performance, and financial metrics, including a negative EPS but healthy revenue growth. The analysis concludes by weighing risks against technological capabilities for investors with higher risk tolerance.
10x Genomics, Inc. (TXG) Stock Analysis: A 52.56% Potential Upside Amidst a Challenging Market
10x Genomics (NASDAQ: TXG) is an intriguing investment opportunity in the healthcare sector, offering a potential 52.56% upside according to analyst ratings despite current market challenges. The company, known for its innovative biological analysis platforms, is currently trading significantly below its 52-week high. While it faces profitability issues with a negative EPS and return on equity, its robust free cash flow and strong market position in R&D driven biotechnology suggest long-term growth potential for investors tolerant of volatility.
10x genomics CEO Serge Saxonov sells $84,393 in stock
Serge Saxonov, CEO of 10x Genomics, sold 7,942 shares of the company's Class A common stock for approximately $84,393 under a Rule 10b5-1 trading plan. Despite TXG shares experiencing a 76% drop over the past year, Saxonov also exercised options to acquire 50,000 shares. The company reported strong Q4 2024 revenue but missed EPS forecasts, and secured a permanent injunction against Parse Biosciences for patent infringement.
10x Genomics, Inc. (TXG) Stock Analysis: Navigating a 21.85% Potential Upside in Healthcare Innovation
10x Genomics, Inc. (NASDAQ: TXG) is analyzed as a pioneering healthcare company focused on advanced life science technology. Despite current unprofitability with a negative P/E and EPS, the company shows promising revenue growth (12.90%) and a significant potential upside of 21.85% based on analyst target prices. Investors should consider its innovative product suite and positive market sentiment against the challenges of its growth phase.
10x Genomics Hits Illumina With 2 Gene Tech Patent Suits
10x Genomics has filed two federal lawsuits in Delaware against Illumina Inc., alleging infringement of nine genetic sequencing patents. 10x Genomics asserts that Illumina was aware of at least one of these patents due to its involvement in a past $31 million verdict concerning a different company in the biology sector. The lawsuits highlight ongoing patent disputes within the gene technology industry.
10x Genomics Hits Illumina With 2 Gene Tech Patent Suits
10x Genomics has filed two patent infringement lawsuits against Illumina Inc. in a Delaware federal court, alleging that Illumina infringed nine genetic sequencing patents. 10x Genomics argues that Illumina was aware of at least one of these patents due to its involvement in a previous $31 million verdict against another company. This action highlights ongoing intellectual property disputes within the gene technology sector.
10x sues rival Illumina over gene-sequencing patents
10x Genomics has filed two lawsuits against Illumina, accusing the rival biotech company of infringing patents related to its genetic analysis technology. 10x claims Illumina's genomics kits and a new gene-analysis platform misuse its innovations for analyzing RNA in tissue samples, while Illumina denies the allegations and plans to vigorously defend itself. This legal action adds to ongoing patent disputes within the genomics industry.
10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences
10x Genomics and Anthropic are collaborating to integrate 10x's single cell and spatial biology analysis tools into Anthropic's Claude for Life Sciences, using the Model Context Protocol. This partnership aims to make complex biological data analysis more accessible to scientists through natural language interaction, removing the need for extensive computational expertise. By leveraging AI, researchers can perform various analytical tasks conversationally, accelerating discovery and breakthroughs in biological research.
10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences
10x Genomics and Anthropic have announced a collaboration to integrate 10x's analysis tools into Anthropic's new Claude for Life Sciences offering. This partnership will allow researchers to interact with complex single cell and spatial biology datasets conversationally using natural language, rather than requiring computational expertise. The goal is to lower technical barriers, accelerate discoveries, and make advanced biological analysis more accessible to a broader scientific community.
10X Genomics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
10X Genomics, Inc. (stock price $11.60) has seen its stock evaluation revised due to market dynamics, experiencing significant volatility over the past year with a high of $18.21 and a low of $6.78. The company's stock performance has significantly declined compared to the S&P 500 across various timeframes, including a 28.66% drop over the last year and over 90% declines over five and ten years. Technical indicators show a mixed trend, with mildly bearish signals from MACD and Bollinger Bands on weekly and monthly bases, but a mildly bullish trend from moving averages daily.
10X Genomics Experiences Evaluation Revision Amidst Market Dynamics and Performance Challenges - Markets Mojo
10X Genomics Inc. has undergone an evaluation revision due to ongoing market challenges, with its stock price at $13.04 and a 44.46% return over the past year. Technical indicators show mixed signals, including bullish MACD and varied Bollinger Bands, highlighting significant volatility and challenges in a competitive market. The company also faces overall risky performance and undervaluation compared to historical averages.
10X Genomics Hits Day Low of $11.54 Amid Price Pressure - Markets Mojo
10X Genomics, Inc. experienced a significant stock price drop, reaching an intraday low of USD 11.54, contributing to substantial year-to-date and annual declines. Despite high institutional ownership and strong operating cash flow, the company is challenged by negative EBITDA and long-term underperformance compared to the S&P 500. This downturn highlights ongoing difficulties in its market position within the Pharmaceuticals & Biotechnology sector.
10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025
10x Genomics, Inc. (Nasdaq: TXG) announced it will release its third-quarter 2025 financial results after market close on Thursday, November 6, 2025. The company will also host a conference call and live webcast for analysts and investors at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results, business developments, and future outlook. The news release and webcast will be available on the company's investor relations website.
1,500 Patients Worldwide: 10x Genomics' Groundbreaking Study Could End Painful Bone Marrow Tests
10x Genomics, in collaboration with CLISEQ Ltd. and the Weizmann Institute, has launched the PERIBLOOD clinical trial, a three-year international study involving over 1,500 participants. This groundbreaking research aims to validate single cell RNA sequencing as a non-invasive alternative to bone marrow aspiration for diagnosing blood disorders, replacing painful procedures with simple blood draws. The study utilizes 10x Genomics' Chromium GEM-X Single Cell technology, building on previous research that demonstrated successful MDS diagnosis from peripheral blood.
Earnings Beat: 10x Genomics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
10x Genomics (NASDAQ:TXG) recently surpassed analyst revenue forecasts and delivered a surprise statutory profit, leading to an increase in optimism among analysts and a favorable reduction in loss per share forecasts. Despite a projected revenue decline compared to the previous year and an expected underperformance relative to the wider industry, analysts have raised their consensus price target by 11% to US$15.00, citing improved intrinsic value. Investors are encouraged to consider the company's longer-term trajectory, with further details available on Simply Wall St's platform.
10x Genomics Settles Patent Dispute With Bruker
10x Genomics has settled a global patent dispute with Bruker Corporation, which involves Bruker paying 10x Genomics $68 million in quarterly installments from Q3 2025 to Q2 2026, plus continuous royalties on spatial biology product sales. The settlement includes global patent cross-licenses and terminates all legal actions in the US, Germany, and the European Unified Patent Court, safeguarding 10x Genomics' intellectual property and enabling continued innovation.
Cathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could Benefit
Cathie Wood, CEO of Ark Invest, emphasized the "profound application" of AI in healthcare, citing new Mass General Brigham research where AI analyzed facial photographs to predict cancer survival outcomes. She believes healthcare will be AI's most impactful application, despite autonomous vehicles and robots being larger in the short term. Companies like Twist Bioscience, Tempus AI, 10X Genomics, and Illumina are positioned to benefit as they develop tools for AI-powered multiomics research and diagnostics.
10x Genomics (NASDAQ:TXG) shareholders have endured a 90% loss from investing in the stock five years ago
Shareholders of 10x Genomics (NASDAQ:TXG) have experienced a significant 90% loss over the past five years, with a 67% decline in the last twelve months and 43% in the most recent quarter. Despite revenue growth of 18% per year over five years, the market appears concerned about the company's lack of profitability and the slow conversion of revenue into profits. Insider buying activity suggests some positive sentiment, but investors are advised to carefully consider the balance sheet strength and other financial indicators.
TXG Stock Price, News & Analysis
10x Genomics, Inc. (NASDAQ: TXG) is a life science technology company specializing in single cell and spatial biology solutions. The company provides instruments, consumables, and software used by academic and biopharmaceutical researchers to analyze biological systems for advancements in oncology, immunology, and neuroscience. TXG's financial performance, stock data, and recent news, including upcoming earnings reports and SEC filings, are detailed in the article.
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025
10x Genomics, Inc. announced they will report their financial results for the first quarter ending March 31, 2025, after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors to discuss the results, business developments, and outlook. The webcast will be accessible on the "Investors" section of their website and archived for replay.
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025
10x Genomics, Inc. (Nasdaq: TXG) will report its Q1 2025 financial results on Thursday, May 8, 2025, after market close. The company will host a public conference call and live webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss their results, business developments, and outlook. Financial results will be available on their website prior to the call.
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
10x Genomics announced its 2025 product roadmap at the AGBT General Meeting, focusing on significant innovations for single cell and spatial biology. The company plans to introduce plate-based workflows for Chromium GEM-X Flex to enable mega-scale single cell analysis and expand its Visium and Xenium portfolios with new high-resolution and multiomic spatial products. These advancements aim to enhance performance, efficiency, and accessibility for researchers in understanding biological systems.
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
10x Genomics announced its 2025 innovation roadmap at the AGBT General Meeting, focusing on advancing large-scale single cell and spatial analysis. The company plans to introduce plate-based workflows for Chromium GEM-X Flex, enabling high-performance, mega-scale single cell research, and expand its Visium and Xenium portfolios with new features like Visium HD 3', Visium HD Cell Segmentation, and Xenium RNA+Protein Multiomics for enhanced spatial biology insights. These innovations aim to push the boundaries of biological discovery and improve efficiency and ease of use for researchers.
10x Genomics and Beckman Coulter Life Sciences Launch New Solution to Automate Single Cell Assay Workflows
10x Genomics and Beckman Coulter Life Sciences have introduced an automated solution for single cell gene expression workflows. This new offering combines an automation-friendly library preparation kit from 10x Genomics with an optimized method from Beckman Coulter Life Sciences, aiming to increase throughput and reduce hands-on time in large-scale single cell studies. The collaboration helps expedite scientific discoveries by streamlining processes and maintaining performance identical to manual workflows while saving significant time.
We Think Some Shareholders May Hesitate To Increase 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation
10x Genomics, Inc.'s CEO, Serge Saxonov, received $8.3 million in total compensation in 2023, which is in line with industry averages for companies of similar market capitalization. Despite a 34% annual EPS growth over three years, shareholder returns have declined by 89% in the same period, suggesting a disconnect between company fundamentals and stock performance. Shareholders are encouraged to express their concerns regarding CEO compensation and the reasons for the stock's underperformance at the upcoming Annual General Meeting on June 11th.
10x Genomics Launches Xenium Catalyst Network
10x Genomics, a leader in single cell and spatial biology, has launched its Xenium Catalyst Network, a global initiative to provide researchers accelerated access to Xenium proof-of-concept data. This network expands the existing Catalyst Program, offering researchers the ability to test Xenium's performance on their own samples for grant applications, funding, and purchasing decisions. The initial network includes K2bio, Macrogen Inc., BioChain Institute Inc., and The McDonnell Genome Institute, with more institutions expected to join in 2024.
10x Genomics Surpasses 100 Xenium Analyzer Shipments
10x Genomics announced that it has shipped over 100 Xenium Analyzer instruments within eight months of its launch, demonstrating strong customer demand and the platform's recognized performance in in situ analysis. Researchers are using the Xenium platform to gain new insights into health and disease with its ease of use, high sensitivity, and comprehensive data analysis capabilities. The company plans future enhancements including multi-modal cell segmentation, higher plex gene panels, and in-line protein assays.
10x Genomics Surpasses 100 Xenium Analyzer Shipments
10x Genomics announced it has shipped over 100 Xenium Analyzer instruments within eight months of its launch, demonstrating strong customer demand and rapid adoption for the in situ analysis platform. Researchers laud the platform for its ease of use, high performance, and ability to provide unprecedented insights into molecular pathology. The company also outlined a multi-year product development roadmap for Xenium, including multi-modal cell segmentation, higher plex gene panels, and in-line protein assays.
10x Genomics Stock: The Illumina of Single-Cell Analysis?
This article examines the trajectory of 10x Genomics (TXG), a company specializing in single-cell analysis, often compared to Illumina (ILMN) in its early days. It details the company's litigious history, rapid revenue growth followed by a recent slowdown in 2022, and its strategy to expand into spatial analysis. The article also discusses increasing competition and ongoing lawsuits, raising questions about the sustainability of 10x Genomics' market dominance as it transitions to new platforms.
